Yesterday was a big day here at Nephron Research as we hosted the first of our quarterly Healthcare Services Symposia series in New York. Thursday’s symposium tackled critical topics in pharmaceutical pricing and benefit management head-on, bringing Biopharma, PBM and Payor leadership together in a single event (including one fire-cracker of a pricing panel). The results didn’t disappoint, and we walked away with numerous insights from the exchange. A few highlights:
- Prime Therapeutics made a compelling case for its transparent PBM model – we foresee share gains with greater exposure at CI/ESRX than CVS/AET
- UPMC Health Plan and Horizon BCBS demonstrated the benefits of integrated models – and in so doing highlighted the opportunities and challenge faced by CVS/AET, CI/ESRX and also UNH/OptumRx
- The PhRMA/BIO and PCMA(PBM)/AHIP(Payor) associations largely agreed to disagree but did find common ground on value based contracting – the conversation surfaced likely 2018 and 2019 policy battles.
We’re proud of the fact that our independent model aligns us with clients and industry participants in pursuit of thought leadership and excited to have the flexibility to capitalize on it.
firstname.lastname@example.org for more information.